Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA

Published on January 24, 2022

The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.

Continue reading on website
Other news

Onto Innovation (ONTO) is an Incredible Growth Stock: 3 Reasons Why

January 24, 2022
Onto Innovation (ONTO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is a Beat in Store for HCA Healthcare's (HCA) Q4 Earnings?

January 24, 2022
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have gained from rising admissions and higher revenues.